Yuki Gosei Kogyo Co., Ltd. (4531) AI Stock Analysis

• Market Cap: ¥5.76B
• Dividend Yield: 3.41%
• Average Volume (3M): 55.46K
• Price to Earnings (P/E): 6.4
• Beta (1Y): 0.76
• Revenue Growth: 16.98%
• EPS Growth: 16.45%
• Country: JP
• Employees: 290
• Sector: Basic Materials
• Sector Strength: 70
• Industry: Chemicals
• EPS (TTM): 19.66
• Shares Outstanding: 21,974,000
• 10 Day Avg. Volume: 20,360
• 30 Day Avg. Volume: 55,456
• PEG Ratio: 0.09
• Price to Book (P/B): 0.56
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -13.23
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 77 Outperform
• Price Target: ¥289.00 ▲(9.47%Upside)

The overall stock score is driven primarily by strong financial performance and attractive valuation. The company's stable revenue growth and profitability, along with a low P/E ratio and substantial dividend yield, enhance its investment appeal. Technical analysis shows moderate bullish momentum, but the lack of strong directional trends tempers the score.

Yuki Gosei Kogyo Co., Ltd. Business Overview & Revenue Model

Company Description

Yuki Gosei Kogyo Co., Ltd. is a Japanese chemical company primarily engaged in the manufacturing and distribution of fine chemicals. The company specializes in the production of pharmaceutical intermediates, agrochemical intermediates, and other specialty chemicals which are integral to various industrial applications. With a strong focus on research and development, Yuki Gosei Kogyo aims to innovate and provide high-quality chemical products to meet diverse customer needs.

How the Company Makes Money

Yuki Gosei Kogyo Co., Ltd. generates revenue primarily through the sale of its fine chemical products, including pharmaceutical and agrochemical intermediates. These intermediates are essential components used by pharmaceutical and agricultural companies in the production of drugs and crop protection products, respectively. The company leverages its expertise in chemical synthesis and robust R&D capabilities to develop high-value products that meet stringent industry standards. Key revenue streams include direct sales to domestic and international clients in the pharmaceutical and agrochemical sectors. Additionally, Yuki Gosei Kogyo may engage in strategic partnerships and collaborations to enhance its market reach and product offerings. The company's earnings are significantly influenced by its ability to innovate and meet the evolving demands of its customers.

Yuki Gosei Kogyo Co., Ltd. Financial Statement Overview

Summary

Yuki Gosei Kogyo Co., Ltd. shows solid financial health with steady revenue growth and improved profitability margins. The balance sheet remains robust with a stable equity base and manageable debt levels. However, the company faces challenges with negative free cash flow due to high capital expenditures, which need to be managed carefully.

Income Statement

The company has demonstrated consistent revenue growth over the past five years, with a revenue increase from ¥10,717 million in 2020 to ¥15,128 million in 2025. Gross profit margins have been stable, averaging around 20% over recent years, indicating efficient production and pricing strategies. Net profit margins have improved, particularly in the last two years, showing enhanced profitability and cost control. EBITDA margins have also strengthened, reflecting robust operating performance.

Balance Sheet

The balance sheet is strong with an improving equity position, as stockholders' equity has grown from ¥10,535 million in 2020 to ¥13,106 million in 2025. The debt-to-equity ratio has been stable, indicating manageable leverage levels. Return on equity has shown positive trends, suggesting efficient use of equity capital. However, the increasing total debt to ¥8,418 million warrants monitoring for potential leverage risks.

Cash Flow

Operating cash flow has been positive and growing, supporting the company's operational needs. However, free cash flow has been negative in recent years due to significant capital expenditures, which might indicate strategic investments or expansion. The operating cash flow to net income ratio is strong, showcasing good cash conversion efficiency, although consistent negative free cash flow could pose a challenge if not managed well.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	14.85B	15.13B	12.93B	12.84B	12.36B	11.09B
Gross Profit	3.33B	3.23B	3.26B	3.05B	2.36B	1.82B
EBITDA	2.10B	2.23B	1.88B	1.56B	1.18B	1.27B
Net Income	891.00M	896.00M	776.00M	556.00M	248.00M	288.00M
Balance Sheet
Total Assets	26.90B	26.87B	24.37B	22.12B	21.17B	21.00B
Cash, Cash Equivalents and Short-Term Investments	1.07B	973.00M	588.00M	1.14B	1.86B	1.26B
Total Debt	8.39B	8.42B	6.78B	5.58B	5.50B	6.10B
Total Liabilities	14.13B	13.76B	11.94B	10.64B	10.17B	10.05B
Stockholders Equity	12.76B	13.11B	12.43B	11.48B	11.00B	10.95B
Cash Flow
Free Cash Flow	0.00	-1.20B	-1.37B	-490.00M	1.40B	-208.00M
Operating Cash Flow	0.00	2.14B	388.00M	668.00M	1.79B	352.00M
Investing Cash Flow	0.00	-3.25B	-1.89B	-1.24B	-442.00M	-648.00M
Financing Cash Flow	0.00	1.50B	948.00M	-158.00M	-772.00M	106.00M

Yuki Gosei Kogyo Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 264.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4531, the sentiment is Positive. The current price of 264 is below the 20-day moving average (MA) of 265.05, above the 50-day MA of 259.06, and above the 200-day MA of 257.16, indicating a neutral trend. The MACD of 1.27 indicates Positive momentum. The RSI at 52.42 is Neutral, neither overbought nor oversold. The STOCH value of 20.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4531.

Yuki Gosei Kogyo Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4366	78 Outperform	¥7.50B	9.15		3.15%	17.92%	―
4531	77 Outperform	¥5.76B	6.38		3.41%	16.98%	16.45%
4040	76 Outperform	¥7.19B	6.10		2.27%	4.57%	-13.43%
4885	71 Outperform	¥2.94B	8.20		3.13%	10.31%	77.52%
4960	61 Neutral	¥4.31B	32.83		1.33%	5.14%	1.96%
4360	46 Neutral	¥4.31B	521.41		3.00%	-3.17%	-21.99%
Sector *	43 Neutral	AU$1.42B	-6.13	-40.62%	4.05%	-4.78%	-42.91%

Yuki Gosei Kogyo Co., Ltd. Corporate Events

Yuki Gosei Kogyo Co., Ltd. Reports Strong Financial Growth

Yuki Gosei Kogyo Co., Ltd. reported strong financial performance for the nine months ending December 31, 2024, with net sales increasing by 21.4% compared to the same period the previous year. This growth was accompanied by substantial increases in operating income, ordinary income, and net income, reflecting improved operational efficiency and market positioning. The company has not revised its financial forecast for the fiscal year ending March 31, 2025, indicating confidence in its projected growth, which is expected to see a continued increase in net sales and income.